Merus N.V. (MRUS)
NASDAQ: MRUS · IEX Real-Time Price · USD
55.29
+0.48 (0.88%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Merus Revenue
Merus had revenue of $38.34M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $7.89M. In the year 2023, Merus had annual revenue of $43.95M with 5.68% growth.
Revenue (ttm)
$38.34M
Revenue Growth
-11.73%
P/S Ratio
95.53
Revenue / Employee
$167,410
Employees
229
Market Cap
3.66B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | 31.13M | -7.25M | -18.88% |
Dec 31, 2018 | 38.38M | 14.27M | 59.20% |
Dec 31, 2017 | 24.11M | 21.35M | 773.11% |
Dec 31, 2016 | 2.76M | 665.50K | 31.76% |
Dec 31, 2015 | 2.10M | 662.20K | 46.20% |
Dec 31, 2014 | 1.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.56B |
Surgery Partners | 2.79B |
Prestige Consumer Healthcare | 1.13B |
Sotera Health Company | 1.08B |
Neogen | 929.24M |
Waystar Holding | 824.72M |
Guardant Health | 603.73M |
Corcept Therapeutics | 523.53M |
MRUS News
- 6 weeks ago - Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 7 weeks ago - Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 7 weeks ago - Merus Announces Pricing of Upsized Public Offering of Common Shares - GlobeNewsWire
- 7 weeks ago - Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 7 weeks ago - Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC - GlobeNewsWire
- 2 months ago - Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting - GlobeNewsWire
- 2 months ago - Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting - GlobeNewsWire